Press Releases August 18, 2026 08:00 AM

Quantum-Si to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Quantum-Si to Present at H.C. Wainwright 28th Annual Global Investment Conference in September 2026

By Ajmal Hussain
Share
Twitter Reddit Facebook LinkedIn
QSI

Quantum-Si Incorporated announced its participation in the upcoming H.C. Wainwright 28th Annual Global Investment Conference, with company executives scheduled for one-on-one meetings and a fireside chat. The event aims to showcase Quantum-Si's advancements in proteomics technology, particularly its single-molecule protein sequencing platform.

Quantum-Si to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
QSI
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Quantum-Si will participate in a major investment conference in September 2026, providing visibility to investors.
  • CEO Jeff Hawkins will engage in a fireside chat, providing insights about the company and its technology.
  • The company focuses on transforming proteomics with a benchtop platform offering real-time single-molecule protein analysis, impacting biotech and healthcare sectors.

BRANFORD, Conn., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics technology company redefining protein analysis through single-molecule protein sequencing, today announced that it will be participating in the H.C. Wainwright 28th Annual Global Investment Conference taking place at the Lotte New York Palace Hotel, September 14-16, 2026.

Jeff Hawkins, President and Chief Executive Officer, and Jeff Keyes, Chief Financial Officer, will be taking one-on-one meetings throughout the day on Tuesday, September 15, 2026, and Jeff Hawkins will participate in a fireside chat on the same day at 1:30 PM Eastern Time.

A live and archived webcast of the event will be available in the “Investors” section of the Quantum-Si website under Events & Presentations.

About Quantum-Si Incorporated
Quantum-Si is transforming proteomics with a benchtop platform that brings single-molecule protein analysis to every lab, everywhere. The Company’s platform enables real-time kinetic-based detection and allows researchers to move beyond traditional, multistep workflows and directly access dynamic, functional protein insights with unparalleled resolution. By making protein analysis simpler, faster, and more informative, Quantum-Si is accelerating proteomic discoveries to improve the way we live. Learn more at quantum-si.com or follow us on LinkedIn or X.

Investors & Media
Jeff Keyes
Chief Financial Officer
[email protected]


Risks

  • Market adoption of Quantum-Si’s new proteomics platform remains uncertain, which could affect future growth potential.
  • Reliance on continued funding and successful technology development to stay competitive in the rapidly evolving biotechnology sector.
  • Potential delays or challenges in commercialization and scaling may impact financial performance.

More from Press Releases

Inter&Co Delivers Record 3Q26 Net Income of US$76.1 Million, With Strong Growth, Higher Margin and Better Efficiency Nov 12, 2026 Super League to Report Third Quarter 2026 Financial Results on Monday, November 16, 2026 Nov 12, 2026 UroGen Reports $68.0 Million of ZUSDURI Revenue and Provides Third Quarter 2026 Financial Results and Highlights Nov 4, 2026 BioVie Announces Pricing of $4.74 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules Nov 4, 2026 Jasper Therapeutics Announces 1-for-30 Reverse Stock Split Nov 4, 2026